by Heather McKenzie – BioSpace –
Approved Thursday via the FDA’s Commissioner’s National Priority Voucher program, Otarmeni is the first gene therapy for hearing loss—and the first treatment to target an underlying cause of the condition.
Regeneron Pharmaceuticals won approval Thursday for its gene therapy for hearing loss, completing what has for nearly a decade been a milestone in the making—for the company and gene therapy more broadly.
